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BACKGROUND AND PURPOSE
We evaluated the concordance of results from two sets of nonclinical cardiovascular safety studies on pitolisant.
EXPERIMENTAL APPROACH
Nonclinical studies envisaged both in the International Conference on Harmonization (ICH) S7B guideline and Comprehensive
in vitro Pro-arrhythmia Assay (CiPA) initiative were undertaken. The CiPA initiative included in vitro ion channels, stem cell-derived
human ventricular myocytes, and in silico modelling to simulate human ventricular electrophysiology. ICH S7B-recommended
assays included in vitro hERG (KV11.1) channels, in vivo dog studies with follow-up investigations in rabbit Purkinje ﬁbres and the
in vivo Carlsson rabbit pro-arrhythmia model.
KEY RESULTS
Both sets of nonclinical data consistently excluded pitolisant from having clinically relevant QT-liability or pro-arrhythmic po-
tential. CiPA studies revealed pitolisant to have modest calcium channel blocking and late INa reducing activities at high con-
centrations, which resulted in pitolisant reducing dofetilide-induced early after-depolarizations (EADs) in the ICH S7B studies.
Studies in stem cell-derived human cardiomyocytes with dofetilide or E-4031 given alone and in combination with pitolisant
conﬁrmed these properties. In silico modelling conﬁrmed that the ion channel effects measured are consistent with results from
both the stem cell-derived cardiomyocytes and rabbit Purkinje ﬁbres and categorized pitolisant as a drug with low torsadogenic
potential. Results from the two sets of nonclinical studies correlated well with those from two clinical QT studies.
CONCLUSIONS AND IMPLICATIONS
Our ﬁndings support the CiPA initiative but suggest that sponsors should consider investigating drug effects on EADs and the use
of pro-arrhythmia models when the results from CiPA studies are ambiguous.
Abbreviations
APA, amplitude of the action potential; APD, action potential duration; CI, conﬁdence interval; CiPA, Comprehensive
in vitro Proarrhythmia Assay; EADs, early after-depolarizations; hERG, human ether-a-go-go potassium channel; ICH, In-
ternational Conference on Harmonization; iPSC, induced pluripotent stem cell; QTc, QT interval corrected for heart rate;
QTcF, QTc using the Fridericia formula; RMP, resting membrane potential; TdP, torsade de pointes; TQT, thorough QT;
UTA, U-wave to T-wave amplitude; Vmax, maximal velocity of depolarization
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Introduction
In 2005, the International Conference on Harmonization
(ICH) adopted two guidelines, requiring all new drugs to be
evaluated for their effects on the QT interval of the surface
ECG. The nonclinical guideline ICH S7B (ICH, 2005a) recom-
mends an in vitro study on the Kv11.1 channel (hERG), re-
sponsible for the major outward repolarizing current (IKr),
and an in vivo study to be followed, if necessary, by other in-
vestigations such as a repolarization assay measuring action
potential parameters in a suitable in vitro preparation and
the use of pro-arrhythmia models. The other guideline, ICH
E14 (ICH, 2005b), recommends a clinical thorough QT
(TQT) study. However, both guidelines focus on a drug’s effect
on QT interval, rather than its pro-arrhythmic risk. These
guidelines are thought to be inadequate, because they disre-
gard the important role of ion channels other than Kv11.1
(hERG) channels in modulating pro-arrhythmogenic poten-
tial. The TQT study is cost-ineffective (Bouvy et al., 2012)
and aims to quantify precisely an effect (drug-induced in-
crease in QTc interval) that correlates poorly with the actual
risk of pro-arrhythmia (Haverkamp et al., 2001; Shah and
Morganroth, 2015). A positive nonclinical and/or clinical
QT-signal often leads to termination of the drug from further
development (Stockbridge et al., 2013).
Consequently, a new paradigm, referred to as the ‘Com-
prehensive in vitro Proarrhythmia Assay’ (CiPA), is under
consideration for more efﬁcient characterization of a drug’s
pro-arrhythmic potential (Sager et al., 2014). This paradigm
recognizes the critical role of multiple ion channels blockade
and calls for two sets of studies consisting of (a) an in vitro
study of a drug’s effects on multiple ion channels, followed
by incorporating these effects in an in silico model of human
ventricular electrophysiology to predict a drug’s pro-
arrhythmic potential and (b) conﬁrmation of these predic-
tions in vitro using human induced pluripotent stem cell
(iPSC)-derived cardiomyocytes (Mirams et al., 2014; Sager
et al., 2014; Gintant et al., 2016). CiPA also calls for intensive
ECGmonitoring in at least one phase I clinical study (that in-
cludes an active control) which, coupled with exposure-
response analysis, could provide information comparable to
that from a TQT study (Shah and Morganroth, 2012; Darpo
and Garnett, 2013). The CiPA package is expected to be pre-
sented to the ICH E14/S7B discussion group by December
2017 (Colatsky et al., 2016).
Therefore, we undertook a range of ICH S7B- and CiPA-
compliant studies to carefully characterize the cardiac safety
proﬁle of pitolisant and to provide data useful for further
progressing the CiPA initiative. Pitolisant (also known as
BF2.649) is a novel, highly potent and selective histamine
H3 receptor antagonist/inverse agonist, with a Ki value
between 0.3 and 2.4 nM at the human receptor, which en-
hances histaminergic transmission in the brain and thereby
promotes wakefulness (Ligneau et al., 2007). In narcolepsy,
pitolisant signiﬁcantly enhances wakefulness, thereby
reducing sleepiness and cataplexy episodes in the orexin/
mouse narcolepsy model as well as in humans (Lin et al.,
2008; Dauvilliers et al., 2013; Szakacs et al., 2017). With
96% protein-binding (in house data), the maximal mean
total pitolisant serum concentrations are in the order of
~100 ng·mL1 (i.e. 0.30 μM, corresponding to a free drug
concentration of 0.012 μM) at steady state after a 2 week
treatment with 40 mg pitolisant hydrochloride maximal
therapeutic dose. Pitolisant, designated as an orphan drug,
was granted a marketing authorization by the European
Medicines Agency in March 2016 for the treatment of narco-
lepsy with or without cataplexy. In the present manuscript,
we summarize the results of more recent CiPA-style nonclin-
ical studies with pitolisant and compare these with the ﬁnd-
ings from earlier ICH S7B nonclinical studies.
Methods
Compliance with requirements for studies using
animals
Validity. Cardiovascular in vivo investigations were
performed according to ICH S7A and ICH S7B guidance
recommendations.
Ethics, animal protection and statistics. Animal studies are
reported in compliance with the ARRIVE guidelines
(Kilkenny et al., 2010; McGrath and Lilley, 2015). All
animals were used in compliance with the French
legislation regarding the protection of laboratory animals
based successively on EU Directives 1986/609/EU and
2010/63/EU and approved by Ethical Committees C2EA-79
(Bioprojet-Biotech) and C2EA-60 (Contract Research
Organization), when applicable. The numbers of animals
used were determined taking into account the known
variability of the parameters measured and as few as
possible to obtain the necessary information.
Housing and husbandry. SPF New Zealand rabbits
(8–13 weeks old, 2.1–2.7 kg; Centre Lago, 01540 Vonnas,
France) were housed separately in standard conditions
[20 ± 2°C, humidity 50 ± 20%, 20 changes of air (by
volume) an hour with ﬁltered, non-recycled air, 12/12 h
light/dark cycle, light on at 07:00 h] in polycarbonate
housing units with perforated ﬂoor (0.51 m2, height 45 cm,
no bedding) with food (Code 110, Safe, 89120 Augy, France)
and 0.22 μm ﬁltered water ad libitum. Conventional Beagle
dogs (12–20 months old, males 10–15 kg, nulliparous
females 10–13 kg, CEDS, 89120 Mézilles, France) were
housed in single sex groups (three dogs per kennel, 16.2 m2,
no bedding) with free access to food (Code 125, Safe, 89290
Augy, France) and water. Animals were allowed to play in
groups in a large pen once a day. Dogs were checked for
comfort and health every day. After surgery, and during
measurements as appropriate, dogs were housed in
individual cages (ﬂoor area: 1.20 m2, height: 1.8 m, i.e.
regulatory cage size according to the 86/609/CEE directive
in force at the time of the study) under artiﬁcial lighting
(12 h) between 07:00 and 19:00 h in a controlled ambient
target temperature of 18 ± 3°C. During periods between
testing sessions, dogs were kept in groups in the kennel.
In vitro study on Kv11.1 (hERG) channel
current: acute and long-term effects
This study, already required under ICH S7B, investigated the
effects of pitolisant (0.1, 0.3, 1, 3, 10 and 100 μM) on Kv11.1
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tail current in HEK-293 cells stably transfected with hERG
cDNA and maintained in an appropriate culture medium. A
whole-cell patch clamp study was performed on isolated cells
at room temperature. Cells were initially clamped at 80 mV,
and biphasic pulses (4.8 s at +20 mV and then for 5 s at
50 mV) were applied at a 0.067 Hz frequency. After initial
stabilization of the preparation, vehicle for control, increas-
ing concentrations of pitolisant and 100 nM of E-4031 (the
reference positive compound) were perfused until equilib-
rium, which was reached in approximately 10 min for each
condition in three to four cells per condition. Peak tail cur-
rent amplitudes for each concentration were measured and
averaged for four consecutive stimuli. Vehicle control tested
in parallel evaluated the spontaneous run-down of hERG cur-
rent over time in testing conditions and the corresponding
correction was applied.
Although the hERG channel assay is considered to be the
method of choice in safety pharmacology for investigating
QT-related risk assessment, it may fail to identify substances
which have an indirect effect (and thus prolong QT interval)
through inhibition of hERG protein trafﬁcking from the en-
doplasmic reticulum to the cell membrane, thus highlighting
a possible limitation of acute short-term screening.
Consequently, the effect of pitolisant on hERG channel
trafﬁcking was investigated in vitro by studying effects on
peak tail current amplitude after long-term (over 24 h) appli-
cation of pitolisant to HEK-293 cells stably transfected with
hERG cDNA. The concentration used (1 μM) was close to its
hERG IC50 value reported above. The effect of pitolisant was
compared to that of pentamidine (10 μM), a reference com-
pound known to reduce this current by inhibiting hERG traf-
ﬁcking, after a long exposure and without any acute effect.
The test after chronic pitolisant exposure, with no noticeable
degradation of the drug substance, was performed without
any pitolisant (i.e. replacement of the cell culture medium
by a fresh pitolisant-free medium just before the patch clamp
test). In parallel, acute effects of pitolisant (0.3 and 1 μM) and
pentamidine (10 μM) were also measured. Whole-cell patch
clamp conditions were similar to the previous one with the
following slight changes (biphasic pulses 2 s at +20 mV and
then for 3.2 s at 50 mV applied at a 0.1 Hz).
In vitro studies on other ion channels
The whole-cell patch clamp technique was used to investigate
the effect of pitolisant on major cardiac currents, namely
peak and late INa (NaV1.5), Ito (KV4.3), IKs (KV7.1/mink),
IK1 (Kir2.1), IKur (KV1.5), ICaL (CaV1.2) and ICaT (CaV3.2),
currents under consideration as part of the CiPA initiative.
HEK-293 or CHO cells were stably transfected with cDNA of
the different ion channels andmaintained in appropriate cul-
ture medium. As shown in Table 1, the effect of pitolisant on
each ion current was studied in four cells per ion channel by
whole-cell patch clamp in standard testing conditions (see
Supporting Information Tables S1 and S2) using standard
drugs as the positive controls (with an assay-to-assay variabil-
ity within ±5% in their inhibitory responses for the various
ion channel assays).
In silico action potential modelling
Mathematical models of cardiac electrophysiology that can
provide predictions of the combined effect of multiple ion
channel blockade (Mirams et al., 2011) have been proposed
as a tool for cardiac safety testing (Mirams et al., 2012; Sager
et al., 2014), and the reader is referred to these references for
an introduction to these models. The IC50 values, ﬁtted to
ion channel data and summarized in Table 1, formed the in-
put into our models for simulating action potentials in
cardiomyocytes. We ran simulations of ion channel block
caused by pitolisant using the ‘ApPredict’Web Portal (Williams
and Mirams, 2015), with predictions of torsadogenic risk
using the model proposed by Grandi et al. (2010) and a
method proposed earlier (Mirams et al., 2011) to predict
Table 1
Effects of pitolisant on human cardiac ion channel currents
Ion channel
Channel
current
Pitolisant
IC50 (μM) Fitted IC50 (μM)
Reference compound
and % inhibition
Outward repolarizing currents
KV11.1 IKr (hERG) 1.3 1.3 E-4031 (100 nM): 86%
KV7.1/mink IKs >10 No effect Meﬂoquine (10 μM): 61%
KV1.5 IKur ≥10 13.8 Terfenadine (10 μM): 81%
KV4.3 Ito ~10 11.4 Dapoxetine (30 μM): 74%
Inward depolarizing currents
NaV1.5 resting state INa >10 26.4
a Lidocaine (10 mM): 99%
NaV1.5 fast inactivated state INa ≥10 26.4a Lidocaine (10 mM): 99%
NaV1.5 slow inactivated state INa ≥10 26.4a Lidocaine (10 mM): 93%
CaV1.2 ICaL ~10 9.5 Nifedipine (1 μM): 88%
CaV3.2 ICaT ≥10 25.7 Mibefradil (1 μM): 83%
Kir2.1 IK1 ≥10 16.5 ML 133 (10 μM): 96%
The ‘Fitted IC50’ column gives the values which were used as inputs into the in silico action potential models, after ﬁtting Hill curves, with Hill coefﬁcients
of one, through the available data points.
aFits to fast and slow inactivated Nav1.5 yielded 26.3 and 26.5 μM, respectively, and so the mean 26.4 μM was used for the whole Nav1.5 current.
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torsadogenic risk according to categories recommended by
Redfern et al. (2003). We used the Shannon et al. (2004)
model for comparison with rabbit-based experiments. We
used these models rather than the O’Hara-Rudy model
(O’Hara et al., 2011) suggested by CiPA (Colatsky et al.,
2016) as we had previously validated Grandi model-based
predictions of torsade risk in response to multiple-ion chan-
nel block (Mirams et al., 2011), and the Shannon et al.
(2004) model is rabbit-speciﬁc. In the future, both Grandi
and O’Hara models may require some ‘rebalancing’ of cur-
rents to improve predictions of human drug-induced re-
sponses (Mann et al., 2016).
In vitro effects in rabbit Purkinje fibres
Following a lethal dose of pentobarbital, the hearts of male
New Zealand rabbits were immediately excised and immersed
in a modiﬁed Tyrode solution maintained at room tempera-
ture and previously saturated with O2/CO2 (95%/5%). A piece
of ventricle containing free running Purkinje ﬁbres was ﬁxed
to the silastic bottom of an organ bath perfused with the same
solution maintained at 37°C for 30 min. The preparation was
then superfused with the modiﬁed Tyrode solution and stim-
ulated for 30 min at 2 Hz and then at 1 Hz (2 ms stimulus at
twice threshold). Action potentials were acquired and
analysed to provide measures of various electrophysiological
parameters such as the resting membrane potential (RMP),
maximal velocity of depolarization (Vmax), amplitude of
the action potential (APA) and action potential durationmea-
sured at 50 and 90% of repolarization (APD50 and APD90). Af-
ter a stabilization period of at least 1 h, action potentials
typical for Purkinje ﬁbres were recorded. Action potential re-
producibility and stability were conﬁrmed during a further
20 min stabilization period. The preparation was then
superfused with experimental solutions which included 0.1,
1 and 10 μM pitolisant and 0.1 μM dofetilide alone or to-
gether with 10 μM pitolisant. Each was applied for 20 min
to enable steady state to be reached. In addition, the emer-
gence of early after-depolarizations (EADs), favoured by cal-
cium loading during the late phase 2 of the prolonged
action potential, is recognized as a better marker of pro-
arrhythmic potential than APD prolongation alone. Hence,
we investigated the effects of 1, 3 and 10 μM of pitolisant in
rabbit Purkinje ﬁbres that exhibited induced EADs and trig-
gered activity [manifested in vivo as torsade de pointes (TdP)
and/or ventricular tachycardia] caused by 0.1 μM dofetilide,
a prototype class III antiarrhythmic drug.
In vitro studies in human stem cell-derived
cardiomyocytes
Action potentials in isolated human cardiomyocytes were re-
corded with pitolisant, E-4031 or dofetilide and their combi-
nation using a conventional patch-clamp technique in
whole-cell conﬁguration at room temperature (22 ± 2°C). Hu-
man cardiomyocytes (Cor.4U®, Axiogenesis AG, Cologne,
Germany) were derived from human iPSC. Preparations were
stimulated at 0.5 Hz with 4 ms rectangular pulses from 1 to
1.5 times depolarization threshold to 60 mV. We studied
RMP, APA, action potential durations measured at 20 and
90% repolarization (APD20 and APD90) and APD90-APD20.
Experiments were carried out on 19 cells originating from
19 different culture dishes:
• Four cells for each of three concentrations (1, 3 or 10 μM) of
pitolisant,
• three cells for 0.1 μM E-4031 followed by pitolisant at
10 μM and
• four cells for 0.1 μM dofetilide followed by pitolisant at
10 μM.
In vivo studies
Three in vivo studies using p.o. and/or i.v. doses of pitolisant
were carried out in rabbits and dogs to characterize further
their in vivo electrocardiographic effects and pro-arrhythmic
potential.
Effect of i.v. infusion in anaesthetized rabbits. Since substantial
clinical evidence indicates a greater susceptibility of females
to developing TdP, the study preferentially included female
animals with 22 (81%) of 27 total animals studied being
females. Male animals were allocated to the reference-
treated group (one out of four animals, 75% female rabbits)
and to the 1 mg·kg1 single-dose pitolisant-treated group
(four out of seven animals, 43% female rabbits). All the
other experimental groups were 100% female. Animals were
anaesthetized with sodium pentobarbital (45–60 mg·kg1
i.v.), maintained on a heated pad and mechanically
ventilated with room air. Before surgery and during the
experiment, depth of anaesthesia was conﬁrmed by
demonstrating lack of jaw tone and palpebral and corneal
reﬂexes. A ﬂuid-ﬁlled catheter was inserted into the carotid
artery to measure systemic arterial blood pressure and for
blood sampling. A venous catheter was implanted into the
jugular vein for infusion of drugs. Standard surface ECG
leads I, II and III were monitored continuously to measure
ECG intervals and the occurrence of ventricular
tachyarrhythmia. Measurements of arterial blood pressures
were calculated over 30 s duration at baseline and every
5 min. For automated ECG capture and measurements,
speciﬁc libraries of ECG complexes were built per animal
constituted of 13 ECG complexes measured manually at
5 min intervals. Then, for all determinations, the means of
10–30 consecutive sinus beats were automatically calculated
at each time point (i.e. at the end of the stabilization period
and then every 5 until 60 min after starting drug infusion)
or until the occurrence of premature ventricular beats.
Parameters recorded were systolic, diastolic and mean
arterial blood pressure (mmHg), heart rate (beats·min-1
calculated from RR interval) as well as PR, QRS and QT/QTU
intervals (ms), amplitudes of T-wave and U-wave (mV) and
rhythm disturbances retrieved from ECG signals. The QT
interval was corrected for heart rate using the formula
developed for rabbits (Carlsson et al., 1993) and adapted to
in-house conditions [corrected QT = QT-0.666 (RR-221) in
ms]. The ratio of U-wave to T-wave amplitude (UTA ratio),
an ECG index of pro-arrhythmic potential, was calculated to
normalize the individual variations in repolarization
according to Gbadebo et al. (2002). Ventricular arrhythmia
was deﬁned according to Lambeth conventions (Walker
et al., 1988) with TdP deﬁned as >7 consecutive beats of
polymorphic ventricular tachycardia. Arrhythmia were
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scored according to the following scale: 0 being no
arrhythmia, 1 being premature beats, 2 being auriculo-
ventricular blocks, 3 being ventricular tachycardia and 4
being TdP; and scores correspond to the average of maximal
life-threatening arrhythmias recorded during the
experiment. After a 10 min stabilization period, the rabbits
received i.v. over 60 min either pitolisant as a slow infusion
(1 mg·kg1 single dose or up to 10 mg·kg1 dose range, i.e. 1,
3.3 and 10 mg·kg1 administered over 20 min successive
steps) or clofilium, a selective IKr blocker as a positive
reference, up to 1 mg·kg1 dose range. In a second set of
experiments, rabbits received either pitolisant (3 mg·kg1
single dose) or its vehicle (3.3 mL·kg1·h1 sterile water)
over 30 min and were monitored post-infusion over a
further 30 min washout period. The range of doses was
appropriate for exploring the effects of a wide range of drug
exposures, including maximal concentrations far above
those expected at therapeutic doses. Haemodynamic and
ECG recordings were monitored continuously over 60 min
following the start of infusion.
Effect in anaesthetized methoxamine-sensitized (Carlsson) rabbit
model. The anaesthetized methoxamine-sensitized rabbit
model of TdP is frequently used to study torsadogenic
potential of drugs (Carlsson et al., 1990). Brieﬂy, female
animals were pre-sensitized with i.v. infusion of methoxamine,
an α1-adrenoceptor agonist, delivered at 15 μg·kg
1·min1
(6 mL·h1) over 70 min. Ten minutes later, pitolisant or
cloﬁlium was administered as a slow i.v. infusion, at the rate of
50 or 150 μg·kg1·min1 over 1 h (i.e. 3 or 9 mg·kg1 full dose
over 1 h) or 20.5 μg·kg1·min1 (i.e. 1.2 mg·kg1 full dose over
1 h), respectively. In addition, another set of experiments
investigated effects of the combination of pitolisant
(50 μg·kg1·min1) with cloﬁlium (20.5 μg·kg1·min1). The
selected range of doses ensured that we explored effects of a
wide range of drug exposures, including maximal
concentrations far above those expected at therapeutic doses.
Effect of single p.o. and i.v. doses in conscious telemetered
dogs. Six Beagle dogs (three males and three females) were
used to evaluate the cardiovascular effects of pitolisant in
freely moving animals. Telemetry implantation was performed
as previously described (Lacroix et al., 2003). Approximately
2 weeks later, blood pressure, heart rate and ECG intervals
were recorded per blocks of 30 s at the time points of interest
for 30 min before and for 24 h after administration of test
compound. ECG traces were inspected visually for any rhythm
or conduction abnormalities (such as arrhythmia,
tachyarrhythmia, atrioventricular conduction blocks), and
values of PR, QRS and QT intervals were obtained by a
validated manual reading procedure (mean calculated from
three non-consecutive sinus beats). The QT interval measured
was corrected for heart rate using the Fridericia formula (QTcF)
and the van de Waters formula. Cardiovascular effects of
pitolisant were investigated in two sessions. Five to six dogs
(two or three males and three females) were studied with at
least 48 h between each test session.
The ﬁrst session tested pitolisant given p.o. at 5, 10 and
15 mg·kg1 compared to the vehicle (2 mL·kg1 of water)
with measurement of pitolisant serum levels 1 and 4 h after
dosing. At the highest dose of 15 mg·kg1 p.o., this route
provided an exposure (59 ± 25 ng·mL1), without any adverse
CNS events (i.e. pre-convulsive signs) in this species, close to
the exposure recorded in humans at therapeutic doses. There-
fore, the second session tested pitolisant given i.v. as a single
bolus at 1.5 and 4.5 mg·kg1 (maximal dose by this route was
without any adverse CNS events) in comparison to the vehi-
cle (sterile saline at 0.2 mL·kg1) with pitolisant serum levels
measured 0.5 and 2 h after dosing but also in a full pharmaco-
kinetic independent session (2, 5, 15 and 30min and 1, 2, 4, 8
and 24 h post-dose) to allow a higher drug exposure.
Pitolisant serum levels were assessed by LC-mass spectrome-
try using a validated analytical method.
Data and statistical analyses
The data and statistical analyses comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). Statistical analyses were performed
with Statview version 5.0 (SAS, Cary, NC, USA), GB Stat ver-
sion 6.5 (Dynamic Microsystems, Silver Spring, MD, USA) or
SigmaStat 3.0 (Systat, San Jose, CA, USA), and in all analyses,
P< 0.05 was taken as indicative of statistical signiﬁcance. Fig-
ure legends provide the group size (n) and speciﬁc statistical
tests performed when n was at least ﬁve per group. For all
data, n corresponds to independent values. For ethical rea-
sons (3R rules), the number of animals was reduced to three
to four individuals in some experiments because the effects
were clear enough. In the study with cardiomyocytes, the
magnitude of the effects observed on APDs (together with
Figure 1
Effects of E-4031 and pitolisant on action potential parameters from
human stem cell-derived ventricular cardiomyocytes compared to
simulated effects of pitolisant on human cardiomyocyte action po-
tential parameters using the Grandi et al. model at 1 Hz (inset).
Changes represent mean ± SEM of n percentages calculated from in-
dividual variation of each parameter for each cell versus vehicle
values (n = 4 cells for vehicle and pitolisant, n = 2 for E-4031). Param-
eters are RMP, APA and action potential durations measured at 20
and 90% of repolarization (APD20 and APD90) with corresponding
absolute values for the vehicle at baseline being 86 ± 2 mV,
130 ± 2 mV, 330 ± 21 ms and 604 ± 61 ms respectively.
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corresponding small error bars) did not warrant increasing
the group size above four. No randomization was performed
because of the small group sizes. All parameters stated are
the numerical values measured, which were not inﬂuenced
by any observer-related bias and, therefore, blinding was
not considered to be necessary. For clarity, most values pre-
sented in the ﬁgures are normalized to control/baseline
values to minimize unwanted sources of variation. Statistical
analyses were performed on absolute values measured and
not on percentage changes.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data
from the IUPHAR/BPS Guide to PHARMACOLOGY
(Southan et al., 2016), and are permanently archived in
the Concise Guide to PHARMACOLOGY 2015/16 (Alexander
et al., 2015a,b).
Results
In vitro study on Kv11.1 (hERG) channel
current
Pitolisant inhibited hERG channel current with an IC50 value
of 1.3 μM, thus indicating that it lacks any signiﬁcant hERG
channel blocking activity at concentrations of 0.3 μM or less,
and the reference compound (E-4031) performed as expected
with an IC50 value of 10.7 nM (Table 1). After long-term
exposure to pitolisant (1 μM) over a 24 h period and following
a washout of the incubation medium, there was no signiﬁ-
cant effect on hERG current measured without pitolisant in
the test medium, and a ratio of peak tail current amplitude
over cell capacitance of 62 ± 4 versus 55 ± 5 pA pF1 in con-
trol. There were no signiﬁcant changes in pitolisant concen-
trations in the cell culture medium over the 24 h of
exposure as evidenced by LC-mass spectrometry. As expected,
pentamidine (10 μM), a reference compound known to in-
hibit hERG trafﬁcking, signiﬁcantly inhibited the hERG tail
current amplitude by 57%, a value in good agreement with
the literature (Kuryshev et al., 2005). Thus, chronic exposure
to pitolisant, at least at concentrations up to 1 μM, lacked
any effect on hERG channel trafﬁcking from the endoplasmic
reticulum to the cell membrane.
In vitro studies on other ion channels
Pitolisant was found to have IC50 values of around or above
10 μM for inhibition of NaV1.5 (INa), KV4.3 (Ito), KV7.1/mink
(IKs), Kir2.1 (IK1), KV1.5 (IKur), CaV1.2 (ICaL) and CaV3.2 (ICaT)
Figure 2
Changes induced by pitolisant in action potential parameters in rabbit
Purkinje ﬁbre. Action potential parameters were measured after
20 min of equilibration for each concentration of pitolisant. Basal
values of RMP, Vmax, APA and action potential durations measured
at 50% and 90% of repolarization (APD50 and APD90, respectively)
were 87 ± 3 mV, 727 ± 30 V·s1, 122 ± 1 mV, 165 ± 13 ms and
223 ± 14 ms respectively. Values are expressed as mean ± SEM
changes (as%baseline values) of n= 6 experiments. Statistics (ANOVA
followed by multiple comparison using the Sidak procedure).
Figure 3
Effect of pitolisant on dofetilide-induced early after depolarization (EAD) in rabbit Purkinje ﬁbre. (A) Traces were recorded before and 20 min after
dofetilide application (0.1 μM) at a stimulation rate of 1 Hz. (B) Traces were recorded at a stimulation rate of 0.25 Hz. Action potential recorded in the
presence of dofetilide 0.1 μMexhibited a pronounced early after depolarization (application of dofetilide 0.1 μM for 35min; APD90 = 593ms). Addition
of 1 μMpitolisant did not suppress the EAD (applications of dofetilide 0.1 μMfor 55min and pitolisant 1 μMfor 20min; APD90 = 598ms). In contrast, the
EAD disappeared in the presence of pitolisant 10 μM (applications of dofetilide 0.1 μM for 1 h10 and pitolisant 10 μM for 15 min; APD90 = 275 ms).
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channels. IC50 values of 26.4 μM for NaV1.5 and 9.5 μM on
CaV1.2 were ﬁtted compared with 1.3 μM for KV11.1 (IKr)
(Table 1).
In silico action potential modelling
The simulated effects on action potential parameters for hu-
man at 1 Hz can be seen in the inset of Figure 1. Very little
effect of pitolisant is seen on RMP and APA, as observed in
the experimental stem cell-derived cardiomyocyte assay.
There was little effect on the APDs at concentrations up to
1 μM (well above clinically relevant total drug concentra-
tions, i.e. 0.24 μM at the highest therapeutic dose) and very
similar patterns compared to experimental APD20 and
APD90. This suggests that the ion channel screening panel
we studied has captured the major effects of the compound
as these predictions are in agreement with experimental re-
sults observed in stem cell-derived cardiomyocytes. This
modelling result provides additional conﬁdence in predicting
the overall cardiac safety of pitolisant in the clinic. Themodel
was used to predict a ‘Redfern Risk Category’ of pro-
arrhythmic risk (Redfern et al., 2003) for pitolisant by a
method described previously (Mirams et al., 2011). Our re-
sults categorize pitolisant in Redfern Category 4 (low risk) at
clinical concentrations. We also predicted the effect of
pitolisant in rabbit ventricular cells at 1 Hz to compare with
those recorded in rabbit Purkinje ﬁbre. The simulation re-
sults, shown in Supporting Information Figure S1, are in
broad agreement with the experimental results, described be-
low, conﬁrming that the known ion channel effects are con-
sistent with all the available data.
In vitro effects in rabbit Purkinje fibres
At a concentration of 1 μM, pitolisant had only minimal ef-
fects on electrophysiological parameters of the action poten-
tial in rabbit Purkinje ﬁbres (Figure 2), conﬁrming the results
obtained with the in vitro studies on other ion channels (see
section above). At a higher concentration of 10 μM, there
was a non-signiﬁcant increase (+9 ± 5% vs. the control) in
APD90 and a signiﬁcant decrease in APD50 (27 ± 4% vs. the
control). In addition, there were signiﬁcant decreases in rest-
ing RMP (6 ± 1% vs. the control), in APA (8 ± 3%) and in
Vmax (17 ± 5%), suggesting that at high concentrations,
pitolisant may have an effect on sodium current generally,
not only late but also peak INa. These effects were reversible
following washout except for APD90 prolongation. These
ﬁndings suggest that at high concentrations above free thera-
peutic plasma levels, pitolisant exerts an inhibitory effect on
IKr during phase 3 of the action potential (as evidenced by
Figure 4
Effects of dofetilide alone or in combination with pitolisant on action
potential parameters from human stem cell-derived ventricular
cardiomyocytes. Changes represent mean ± SEM of n percentages
calculated from individual variation of each parameter for each cell
versus vehicle values (n = 4 cells for vehicle, dofetilide alone and com-
bination of dofetilide and pitolisant). Parameters are RMP, APA and
action potential durations measured at 20 and 90% of repolarization
(APD20 and APD90) with corresponding absolute values for the vehi-
cle at baseline being 88 ± 3 mV, 125 ± 4 mV, 344 ± 54 ms and
635 ± 75 ms respectively.
Table 2
Effects of infusions of pitolisant or cloﬁlium on QTc interval (ms) in anaesthetized rabbits
Dose
(n)
Cloﬁlium Pitolisant
1 mg·kg1 1 mg·kg1 10 mg·kg1 dose range
(4) (7) (4)
QTc interval (ms) (mean ± SEM)
Baseline 152 ± 2 152 ± 3 144 ± 4
Time (min) into infusion
10 152 ± 2 154 ± 2 148 ± 3
20 157 ± 3 156 ± 2 149 ± 2
30 168 ± 5 156 ± 2 151 ± 2
40 172 ± 8 156 ± 2 151 ± 1
50 – 157 ± 2 148 ± 4
60 – 157 ± 3 147 ± 2
Cloﬁlium was infused over 1 h at a dose of 1 mg·kg1. Pitolisant was infused over 1 h at the dose of 1 mg·kg1 or successively over 20 min at 1, 3.3 and
10 mg·kg1. QT interval was corrected for variation in heart rate using the formula developed for rabbits (Carlsson et al., 1993) and adapted to in-house
conditions [QTc = QT-0.666·(RR-221) with QT and RR durations in ms], QTc interval values provided are mean ± SEM.
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an increase in APD90) and on L-type calcium channels (as ev-
idenced by the decrease of 27% in APD50, corresponding to
an estimated IC50 value of about 5 μM for APD50).
Effect on early after-depolarizations and triggered
activity. Dofetilide consistently and predictably induced
EADs or triggered activity in all 10 preparations, and
pitolisant had a dose-related EAD-mitigating effect
(Figure 3). Application of 1 μM of pitolisant had no effect
(in four out of four experiments) while 3 μM was effective in
inhibiting dofetilide-induced EADs in two out of three
experiments. Pitolisant might be suspected to favour the
occurrence of EADs because of triangulation of action
potential shape (see Figures 2 and 3). However, 10 μM of
pitolisant always suppressed dofetilide-induced EADs in all
seven experiments and dofetilide-induced spontaneous
triggered activity in one out of one experiment. Pitolisant
eliminated, rather than exacerbated, the pro-arrhythmic
effect of dofetilide.
In vitro studies in human stem cell-derived
cardiomyocytes
Results from this study showed that pitolisant had little ef-
fect on RMP and APA. Results for APD20 and APD90
(Figures 1 and 4) and APD90-APD20 (not shown) showed that
a Pitolisant had a concentration-dependent effect of decreas-
ing APD20, suggesting L-type calcium channel block at high
concentrations (≥3 μM).
b Pitolisant prolonged APD90, suggesting some hERG chan-
nel inhibition at concentrations ≥1 μM. At higher concen-
trations (10 μM), the effect on APD90 was much
attenuated, suggesting compensatory effects of pitolisant
mediated by action(s) on additional ion channel(s).
c Pitolisant at 3 μM elicited a maximal increase of 97 ms in
APD90 compared to the effect (increase of 120 ms) of
0.1 μM of E-4031, a classical potent hERG channel blocker.
Effect of higher concentrations of pitolisant on APD90–20
(increase of 192 and 176 ms vs. baseline at 3 and 10 μM
compared to the increase of 253 ms for 0.1 μM of E-4031)
Figure 5
Incidence of ventricular arrhythmias in methoxamine-sensitized rabbits infused with cloﬁlium tosylate, pitolisant and their combination. Ventric-
ular arrhythmias were assessed according to the Lambeth conventions in groups treated with pitolisant (50 μg·kg1·min1), cloﬁlium tosylate
(20.5 μg·kg1·min1) or the combination of both drugs. (Left) Mean ± SEM UTA ratio (% of pre-drug value) over time (top) and arrhythmia score
evaluated for each experimental group (bottom). (Right) Horizontal bars are schematic representation of occurrence of rhythm abnormalities
over time for each cloﬁlium-treated rabbit (#1 to #8), in the absence (top) or in the presence (bottom) of concomitant pitolisant infusion.
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was consistent with concentration-dependent effects on
hERG and L-type calcium channels.
d Effects of dofetilide on APD20 and APD90 were consistent
with the data described for this compound (mainly an in-
crease in APD90).
e At a high concentration, pitolisant potentiated the small
effect of dofetilide on APD20. Interestingly, pitolisant also
fully reversed dofetilide-induced increase in APD90, sug-
gesting perhaps a calcium channel blocking activity.
In vivo studies
As described in the Methods, three in vivo studies in two
different species (rabbit and dog), using p.o. and/or i.v.
doses of pitolisant, were carried out to further characterize
their in vivo electrocardiographic effects, including any
pro-arrhythmic signals. Regarding drug exposure, it is
worth emphasizing that the protein binding of pitolisant
is about 96% in all animal species studied and in humans
(in-house data).
Effect of i.v. infusion in anaesthetized rabbits. Effects of
pitolisant (up to 10 mg·kg1 by slow i.v. infusion) were
compared to those of cloﬁlium, a selective IKr blocker (up to
1 mg·kg1). Pitolisant, when given as a single dose
(1 mg·kg1 over 60 min), did not cause any signiﬁcant
change in heart rate, QTc interval (+3 ± 1%) or blood
pressure (data not shown). After cumulative infusion with 1,
3.3 and 10 mg·kg1 in successive 20 min steps (i.e. 50, 160
and 500 μg·kg1·min1), ensuring a maximal total drug
exposure of 4140 ± 450 ng·mL1 (i.e. total drug
concentration of 13.8 ± 1.5 μM which corresponds to free
drug concentration of ~0.55 μM), heart rate decreased by
17 ± 4%. However, no prolongation of QTc interval was
Figure 6
Effects of cloﬁlium tosylate, pitolisant and their combination on heart rate and ECG parameters in methoxamine-sensitized anaesthetized rabbits.
Mean ± SEM changes in ECG parameters (when measurable) during the 60 min infusion period in methoxamine-treated rabbits. QT interval was
corrected for variation in heart rate using the formula developed for rabbits (Carlsson et al., 1993) and adapted to in house conditions [QTc =
QT-0.666·(RR-221) with QT and RR durations in ms]. Open circles: pitolisant 50 μg·kg1·min1(n = 3 animals); open squares: cloﬁlium tosylate
20.5 μg·kg1·min1(n = 4); solid squares: a combination of both (n = 4).
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recorded (2 ± 1% vs. baseline, Table 2). In contrast, cloﬁlium
induced a prolongation of QTc interval (+13 ± 5% vs.
baseline, Table 2) and other ECG abnormalities (shortening
of PR interval and prolongation of QRS interval – data not
shown). Pitolisant elicited some changes in the terminal
portion of repolarization (appearance of U waves) in some
ECGs. However, although the incidence of U waves was
higher, there was no major change in the UTA ratio (data
not shown). Ventricular arrhythmias were never observed
in the vehicle and in pitolisant-treated (up to 10 mg·kg1
by i.v. slow infusion) groups evidencing a low pro-
arrhythmic potential of pitolisant. In contrast, cloﬁlium
infusion induced severe ventricular tachyarrhythmia;
none of these animals remained in sinus rhythm at the
end of the experiment. The ventricular tachycardia
incidence was 100% (n = 4/4 experiments), and TdP
occurred in 75% of experiments (n = 3/4) in the cloﬁlium-
treated group. Interestingly, pitolisant (10 mg·kg1)
abolished ventricular premature beats, ventricular
tachycardia and TdP induced by cloﬁlium (1 mg·kg1) in
this preparation (data not shown).
Effect in anaesthetized methoxamine-sensitized (Carlsson) rabbit
model. In this model, pitolisant alone was devoid of any
Figure 7
Haemodynamic and repolarization effects following p.o. and i.v. doses of pitolisant in conscious telemetry-implanted dogs. Changes in mean ar-
terial blood pressure, heart rate and QTcF interval following p.o. (panels on left) and i.v. (panels on right) doses of pitolisant and the vehicle.
Mean ± SEM of values recorded in n = 6 dogs. Statistics (ANOVA followed by a Dunnett’s test).
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effect on QTc interval, and it lacked any pro-arrhythmic
effect even at high total drug concentrations (1062 ± 125
and 3387 ± 1226 ng·mL1, i.e. 3.5 ± 0.4 and 11.3 ± 4.1 μM,
corresponding to free drug concentrations of ~0.14 and
0.45 μM, after the 50 and 150 μg·kg1·min1 1 h infusion,
respectively) well above the concentrations achieved
clinically. There were, however, minor morphological
changes as demonstrated by a small increase in UTA ratio
(Figure 5). In contrast, cloﬁlium rapidly induced ECG
changes (bradycardia, prolongation of QTc interval and a
marked 90% increase in UTA ratio) that resulted in
ventricular tachyarrhythmia (Figures 5 and 6).
Administration of a combination of pitolisant and cloﬁlium
elicited no change in QTc interval but a marked bradycardia
(Figure 6). Interestingly, administration of pitolisant
concurrently with cloﬁlium normalized the UTA ratio,
which was almost doubled under cloﬁlium alone.
Furthermore, the pro-arrhythmic potential of cloﬁlium was
reduced by combining it with pitolisant (Figure 5).
Effect of single p.o. and i.v. doses in conscious telemetered
dogs. Compared to the vehicle, single doses of pitolisant
(5, 10 and 15 mg·kg1 p.o. or 1.5 mg·kg1 i.v.) had no effect
on heart rate, mean arterial blood pressure, QTc interval
(Figure 7) or any other ECG parameter (data not shown).
Blood samples collected 1 and 4 h after dosing
demonstrated relatively low total drug exposure of animals
receiving pitolisant p.o. (3.5 ± 1.0, 15.8 ± 5.8 and
59.2 ± 24.6 ng·mL1 at 1 h after the administration of 5, 10
and 15 mg·kg1 pitolisant, respectively) and a high
variability between dogs. The exposure in animals receiving
the i.v. dose of 1.5 mg·kg1 was satisfactory, with total drug
concentrations reaching 294 ± 40 ng·mL1 at 5 min and
231 ± 36 ng·mL1 at 30 min.
Much higher exposure was achieved after the i.v. dose of
4.5 mg·kg1 with total drug concentrations reaching 1044 ±
570 ng·mL1 (3.48 ± 1.90 μM) at 5 min, 579 ± 187 ng·mL1
(1.93 ± 0.62 μM) at 30 min and 159 ± 49 ng·mL1
(0.53 ± 0.16 μM) at 4 h (bearing in mind that total drug con-
centration of 3.5 μM corresponds to free drug concentration
of ~0.14 μM). This resulted in increases inmean arterial blood
pressure and heart rate for up to 4 h after injection (Figure 7).
It produced a decrease in QTcF interval for 20 min with a re-
turn to baseline 30 min after injection (Figure 7). Thereafter,
there was no signiﬁcant difference between the vehicle and
pitolisant for a period up to 24 h. Use of van de Water’s
formula to correct the measured QT interval resulted in
ﬁndings (not shown) similar to those following the applica-
tion of Fridericia correction. No arrhythmia or other morpho-
logical changes in the ECG attributable to pitolisant were
observed over the test period in 6/6 dogs. Exposure to high
total drug concentration of pitolisant could account for the
hypertension and tachycardia observed at the 4.5 mg·kg1
i.v. dose as pitolisant had some activity at α2-adrenoceptors
with Ki values of 2.9, 4.3 and 1.2 μM for α2A, α2B and
α2C-adrenoceptors respectively. The transient decrease
in QTcF interval, although statistically signiﬁcant, is likely
spurious, resulting from marked increase in heart rate since,
in presence of large changes in heart rate, there is much less
conﬁdence in the Fridericia corrected QTc intervals.
Discussion and conclusions
Nonclinical results on pitolisant across both ICH S7B and
CiPA initiative studies are consistent and, as discussed hereaf-
ter, correlate well with data from clinical trials.
The ICH S7B studies showed that pitolisant has a mini-
mal hERG channel blocking activity at concentrations up
to 0.3 μM. Its IC50 value for hERG blockade is 1.3 μM
which corresponds to a safety margin around 100, assum-
ing 96% protein-binding (in house data) and maximal
mean total pitolisant serum concentrations of ~100
ng·mL1 (i.e. 0.30 μM, corresponding to a free drug concen-
tration of 0.012 μM) at steady state after a 2 week treatment
with the 40 mg pitolisant hydrochloride maximal therapeu-
tic dose (Lin et al., 2008). This safety margin is typical for
QT prolonging drugs which lack a pro-arrhythmic potential.
In addition, no effect on the hERG current was measured in
absence of pitolisant following pre-test exposure to
pitolisant for 24 h showing that pitolisant does not inhibit
hERG channel trafﬁcking. Recently, Obejero-Paz et al.
(2015) have suggested that an hERG trafﬁcking assessment
should be added to the CiPA package. In vitro ion channel
studies, performed according to CiPA-style proposals, sug-
gested pitolisant to have modest calcium channel blocking
as well as late INa reducing activities. These ion channel data,
integrated using an in silico electrophysiology model, elicited
an action potential for pitolisant rather similar to the one ex-
perimentally recorded in human ventricular cardiomyocytes.
This, together with the high IC50 values (> or ~10 μM) of
pitolisant for these channels relative to the hERG channel
(IC50 ~ 1.3 μM), suggests that high concentrations of
pitolisant are required for a clinically relevant block of these
channels to mitigate the pro-arrhythmic effect of any hERG
blockade. In this context, supra-therapeutic concentrations
of pitolisant prevented dofetilide-induced increase in APD90
in human iPSC cardiomyocytes. Our cardiomyocyte results
are in line with data from larger assessments of iPSC
cardiomyocytes for evaluating drug-induced arrhythmias
proposed as part of the CiPA initiative, that is, APD prolonga-
tion and arrhythmia with hERG channel blocking drugs
and APD shortening and prevention of arrhythmia with
calcium channel blocking drugs (Blinova et al., 2017).
Both calcium channel blocking as well as late INa reducing
activities have already been reported to reduce any risk of
proarrhythmia due to hERG channel blockade and QT inter-
val prolongation. Hence, to mitigate the pro-arrhythmic ef-
fect of hERG blockade, the IC50 values for the L-type
calcium and/or the late INa currents should be fairly close to
the one for IKr. Examples are ranolazine (Antzelevitch
et al., 2014; Crumb et al., 2016), verapamil (Obejero-Paz
et al., 2015; Crumb et al., 2016) and mexiletine (Gao et al.,
2013; Antzelevitch et al., 2014; Gualdani et al., 2015; Crumb
et al., 2016). There are no well-documented reports of TdP
in association with their use.
In contrast, the development of 400mg vanoxerine in the
treatment of atrial ﬁbrillation had to be discontinued because
of unacceptably high prevalence of TdP (Piccini et al., 2016).
Its IC50 value for hERG channel was just over ninefold greater
than that for the late INa current (9.3 and 85.2 nM, respec-
tively; Obejero-Paz et al., 2015). We note that vanoxerine is
140-fold more potent than pitolisant in inhibiting the hERG
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channel, and clinically, it induced dose-dependent increases
in QTcF interval (mean of 32.2 ms on 200 mg dose, 51.3 on
300 mg and 60.7 ms on 400 mg) (Dittrich et al., 2015).
Importantly, however, there is insufﬁcient information
regarding the degree of block of the L-type calcium and
reduction in late INa currents required in vivo for a clinically
meaningful and beneﬁcial effect in terms of reducing
pro-arrhythmic risk. Recent in vitro studies have shown that
mexiletine inhibits late INa with an IC50 value of
17.6 ± 1.9 μM and fast INa with an IC50 value of
34.6 ± 2.9 μM (Gao et al., 2013) and hERG channel with an
IC50 value of 3.7 ± 0.7 μM (Gualdani et al., 2015). In a study
in canine Purkinje ﬁbres, erythromycin induced a pro-
nounced prolongation of APD and the appearance of EADs
in all Purkinje preparations (9/9). After addition of mexiletine
(10 mM), erythromycin-induced prolongation of APD short-
ened markedly and EADs disappeared (7/9) (Fazekas et al.,
1998). The therapeutic concentrations of mexiletine range
from 3.4 to 9.5 μM, and yet, it is effective in type 3 congenital
LQTS (Mazzanti et al., 2016). Badri et al. (2015) have shown
mexiletine to be also effective in acquired LQT syndrome. In
this context, we note that Johannesen et al. (2016) have re-
ported that their ion channel patch clamp experiments sug-
gest that both mexiletine and lidocaine induce only about
20% block of late sodium current at the concentrations that
caused approximately 20 ms shortening of QTc. Even
ranolazine, at clinical Cmax, induces only 21% block, com-
pared to only 3% block by quinidine, of late INa (Vicente
et al., 2015). Equally, at clinical concentrations, pitolisant
does not have any meaningful effect on hERG channels that
requires mitigation. However, the possibility that pitolisant
may have a clinically relevant effect on L-type calcium
channel or late INa at concentrations lower than those sug-
gested by its IC50 values cannot be ruled out. IC50 values
determined in in vitro systems are variable (Elkins et al.,
2013) and often do not correlate with in vivo activity
(Makielski, 2016). Plasma concentrations far lower than
IC50 concentrations are known to induce QT interval pro-
longation. In one simulation study, only a 10% hERG
blockade by dofetilide corresponded to a QT prolongation
of 20 ms [95% conﬁdence interval (CI): 12–32 ms] (Jonker
et al., 2005). Similarly, in vivo in humans, smaller effects
on calcium and late INa at lower concentrations (IC15–20
in the range of 0.5–1 μM) may be effective in clinically
relevant reduction of the currents concerned. As noted
earlier, application of 1 μM of pitolisant had no effect in
inhibiting dofetilide-induced EADs, but 3 μM was partially
effective.
These results were in line with those obtained previously
in rabbit Purkinje ﬁbres. In this ICH S7B-compliant follow-
up model, pitolisant exerted inhibitory effect on IKr current
and on L-type calcium channel at high concentrations as ev-
idenced by the increase in the APD90 and the decrease in the
APD50, respectively and eliminated EADs induced by
dofetilide despite its apparent propensity to provoke triangu-
lation of action potential shape.
In vivo nonclinical studies in anaesthetized rabbits and
telemetered dogs revealed either no or inconsistent effects
on the QTc interval. No arrhythmias were observed in any
in vivo animal studies. The study in Carlsson’s rabbit model
further conﬁrmed the lack of a pro-arrhythmic effect, where
pitolisant did not prolong QTc interval or induce any
life-threatening arrhythmia; indeed, it actually reduced the
incidence of cloﬁlium-induced proarrhythmia. In line with
inhibitory potencies of pitolisant at the various cardiac ion
channels, data from these studies also support the conclusion
that pitolisant has no effect on PR and QRS intervals, and lit-
tle or no QT-prolonging activity, at therapeutic mean maxi-
mal total drug concentrations of ~100 ng·mL1 (i.e.
0.30 μM, corresponding to a 0.012 μM free concentration)
at steady state after a 2 week treatment with 40 mg pitolisant
hydrochloride maximal therapeutic dose. At higher doses
which result in concentrations up to 55 times higher than
these, pitolisant has ancillary electrophysiological activity
that can antagonize the pro-arrhythmic effect of other drugs.
The results from both sets of nonclinical studies (ICH
S7B-compliant and CiPA-style) enabled categorization of
pitolisant as a drug with low risk torsadogenic potential
(the principal objective of the CiPA initiative). Indeed, the
CiPA-style studies provided tentative evidence for pitolisant
to have inhibitory effects on calcium and/or late INa cur-
rents which could account for its lack of pro-arrhythmic ef-
fects, even if the inhibition of these currents, compared to
the inhibition of hERG current, is relatively small. The CiPA
ﬁndings were consistent with data from earlier extensive
nonclinical follow-up studies conducted as recommended
in ICH S7B, both conﬁrming its lack of pro-arrhythmic
potential.
Results from both sets of nonclinical studies are also in
good agreement with the effect of pitolisant on QT interval
observed in the clinical SAD and TQT studies (Shah et al.,
2016). Analysis by ICH E14-recommended intersection
union test revealed comparable maximum mean (90% CI)
placebo-corrected increase in QTcF interval from baseline
(ΔΔQTcF) in both the studies, being 3.29 (0.35, 6.23) ms at
40 mg and 5.27 (2.35, 8.20) ms at 120 mg dose in the TQT
study, and 13.3 (8.1, 18.5) ms at 200 mg and 9.9 (4.7, 15.1)
ms at 240 mg doses in the SAD study (all doses expressed as
pitolisant hydrochloride). Corresponding pharmacokinetics
provided Cmax values of 53 ± 27, 164 ± 63 and 282± 47 ng·mL
1
at 40, 120 and 240 mg respectively. Thus, pitolisant, at the
highest clinically relevant exposure of 35 and 72 ng·mL1
(0.12 and 0.24 μM) at 20 and 40 mg daily dosing, respectively,
lacked an effect of regulatory concern onQTc interval. Notwith-
standing, it is acknowledged that to fully support CiPA, one
would need additional data in the clinic, particularly in wider
patient populations. Our ﬁndings are in agreement with the
ﬁndings by Vargas et al. (2015) who reported that 91% of the
drugs that prolong the QT interval in humans also did so in
animals (guinea pigs, rabbits, dogs and non-human primates),
and 88% of the drugs that did not prolong the QT interval in
humans also did not prolong the interval in animals.
In conclusion, our ﬁndings lend support to the CiPA
initiative and suggest that the additional effects at calcium
and sodium channels may enable a distinction to be made
between QT interval prolongation that may be pro-
arrhythmic or antiarrhythmic. However, demonstrating in-
hibitions of the calcium and/or late INa current appears to
be only one in vitro component for the demonstration of
the lack of pro-arrhythmic potential of a drug that may
prolong the QT interval. The present study suggests that
sponsors should consider investigating drug effects on
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EADs and the use of pro-arrhythmia models (such as the
Carlsson rabbit model) when the results from CiPA studies
are ambiguous.
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